These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 22303460)

  • 1. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
    Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
    PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
    Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR
    Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.
    Orillion A; Hashimoto A; Damayanti N; Shen L; Adelaiye-Ogala R; Arisa S; Chintala S; Ordentlich P; Kao C; Elzey B; Gabrilovich D; Pili R
    Clin Cancer Res; 2017 Sep; 23(17):5187-5201. PubMed ID: 28698201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).
    Pili R; Quinn DI; Hammers HJ; Monk P; George S; Dorff TB; Olencki T; Shen L; Orillion A; Lamonica D; Fragomeni RS; Szabo Z; Hutson A; Groman A; Perkins SM; Piekarz R; Carducci MA
    Clin Cancer Res; 2017 Dec; 23(23):7199-7208. PubMed ID: 28939740
    [No Abstract]   [Full Text] [Related]  

  • 6. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
    Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
    Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
    Gameiro SR; Malamas AS; Tsang KY; Ferrone S; Hodge JW
    Oncotarget; 2016 Feb; 7(7):7390-402. PubMed ID: 26862729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
    Smith HJ; McCaw TR; Londono AI; Katre AA; Meza-Perez S; Yang ES; Forero A; Buchsbaum DJ; Randall TD; Straughn JM; Norian LA; Arend RC
    Cancer; 2018 Dec; 124(24):4657-4666. PubMed ID: 30423192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
    Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
    Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.
    Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA
    Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans.
    Choi SW; Gatza E; Hou G; Sun Y; Whitfield J; Song Y; Oravecz-Wilson K; Tawara I; Dinarello CA; Reddy P
    Blood; 2015 Jan; 125(5):815-9. PubMed ID: 25428224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
    Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
    Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulation of HDAC Inhibitor Entinostat Potentiates the Anticancer Effects of Radiation and PD-1 Blockade in the Murine Lewis Lung Carcinoma Model.
    Kim Y; Park K; Kim YJ; Shin SW; Kim YJ; Choi C; Noh JM
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo.
    Glauben R; Sonnenberg E; Wetzel M; Mascagni P; Siegmund B
    J Biol Chem; 2014 Feb; 289(9):6142-51. PubMed ID: 24421314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
    Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
    Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling.
    Liu N; He S; Ma L; Ponnusamy M; Tang J; Tolbert E; Bayliss G; Zhao TC; Yan H; Zhuang S
    PLoS One; 2013; 8(1):e54001. PubMed ID: 23342059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of class I but not class IIb histone deacetylases exerts cardiac protection from ischemia reperfusion.
    Aune SE; Herr DJ; Mani SK; Menick DR
    J Mol Cell Cardiol; 2014 Jul; 72():138-45. PubMed ID: 24632412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
    Jóna A; Khaskhely N; Buglio D; Shafer JA; Derenzini E; Bollard CM; Medeiros LJ; Illés A; Ji Y; Younes A
    Exp Hematol; 2011 Oct; 39(10):1007-1017.e1. PubMed ID: 21767511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.